CY1122470T1 - Αναστολεις kv1.3 και η ιατρικη εφαρμογη αυτων - Google Patents

Αναστολεις kv1.3 και η ιατρικη εφαρμογη αυτων

Info

Publication number
CY1122470T1
CY1122470T1 CY20191101312T CY191101312T CY1122470T1 CY 1122470 T1 CY1122470 T1 CY 1122470T1 CY 20191101312 T CY20191101312 T CY 20191101312T CY 191101312 T CY191101312 T CY 191101312T CY 1122470 T1 CY1122470 T1 CY 1122470T1
Authority
CY
Cyprus
Prior art keywords
group
alkyl
hydrogen
nr4r5
heterocycloalkyl
Prior art date
Application number
CY20191101312T
Other languages
English (en)
Inventor
Stefan Tasler
Ilga KRIMMELBEIN
Jürgen Kraus
Mirko Zaja
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of CY1122470T1 publication Critical patent/CY1122470T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με μια ένωση του γενικού χημικού τύπου (II) ή ένα άλας ή επιδιαλυτωμένο άλας εξ αυτής, ως επίσης και ιατρικές χρήσεις ενέχοντας αυτές, όπου το Α1 επιλέγεται από την ομάδα συνιστάμενη από Ν και C-R8˙ το Α2 επιλέγεται από την ομάδα συνιστάμενη από Ν και C-R3˙ το Α3 επιλέγεται από την ομάδα συνιστάμενη από Ν και C-R9˙ τα Α4 και Α5 και Α6 επιλέγονται ανεξαρτήτως από την ομάδα συνιστάμενη από Ν και C-R1˙ το R1 επιλέγεται από την ομάδα συνιστάμενη από υδρογόνο, (C1-C3)αλκύλιο, αλογόνο, (C1-C3)αλκοξυομάδα, και (C1-C3)αλοαλκύλιο˙ το R2 επιλέγεται από την ομάδα συνιστάμενη από υδρογόνο, αλογόνο, και (C1-C3)αλκύλιο˙ το R3 επιλέγεται από την ομάδα συνιστάμενη από υδρογόνο, (C1-C3)αλκύλιο, NR4R5, (C1-C3)αλκυλ-NR4R5, και κυανομάδα, όπου τα R4 και R5 επιλέγονται ανεξαρτήτως από την ομάδα συνιστάμενη από υδρογόνο, (C3-C5)κυκλοαλκύλιο, (C3-C5)ετεροκυκλοαλκύλιο και (C1-C3)αλκύλιο, ή τα R4 και R5 μαζί με το άτομο αζώτου στο οποίο αυτά προσαρτώνται σχηματίζουν έναν 5- έως 7-μελή ετεροκυκλικό δακτύλιο περιλαμβάνοντας προαιρετικώς επιπλέον στο προαναφερθέν άτομο αζώτου μια περαιτέρω ομάδα ετεροατόμου που επιλέγεται από την ομάδα συνιστάμενη από Ο και NR6, όπου το R6 επιλέγεται από την ομάδα συνιστάμενη από υδρογόνο, μεθύλιο, ακετύλιο και φορμύλιο˙ το Υ επιλέγεται από την ομάδα συνιστάμενη από Ο και S˙ το R8 επιλέγεται από την ομάδα συνιστάμενη από (C1-C4)αλκύλιο, (C3-C5)κυκλοαλκύλιο και (C3-C5)ετεροκυκλοαλκύλιο˙ και το R9 επιλέγεται από την ομάδα συνιστάμενη από υδρογόνο, (C1-C3)αλκύλιο και (C1-C3)αλκυξυομάδα˙ όπου ορισμένες ειδικότερες ενώσεις αποκλείονται από παραδοχή, και μεθόδους για παραγωγή τέτοιων ενώσεων.
CY20191101312T 2015-03-13 2019-12-13 Αναστολεις kv1.3 και η ιατρικη εφαρμογη αυτων CY1122470T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15159080 2015-03-13
PCT/EP2016/055451 WO2016146583A1 (en) 2015-03-13 2016-03-14 Kv1.3 inhibitors and their medical application

Publications (1)

Publication Number Publication Date
CY1122470T1 true CY1122470T1 (el) 2021-01-27

Family

ID=52736854

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101312T CY1122470T1 (el) 2015-03-13 2019-12-13 Αναστολεις kv1.3 και η ιατρικη εφαρμογη αυτων

Country Status (27)

Country Link
US (4) US10822345B2 (el)
EP (1) EP3268374B1 (el)
JP (1) JP6506409B2 (el)
KR (1) KR20170137056A (el)
CN (1) CN107548397B (el)
AU (1) AU2016232338B2 (el)
BR (1) BR112017019439A2 (el)
CA (1) CA2979503A1 (el)
CY (1) CY1122470T1 (el)
DK (1) DK3268374T3 (el)
EA (1) EA037194B1 (el)
ES (1) ES2762938T3 (el)
HK (1) HK1243997B (el)
HR (1) HRP20192258T1 (el)
IL (1) IL254391B (el)
LT (1) LT3268374T (el)
MX (1) MX2017011650A (el)
PH (1) PH12017501652B1 (el)
PL (1) PL3268374T3 (el)
PT (1) PT3268374T (el)
RS (1) RS59758B1 (el)
SG (1) SG11201707284PA (el)
SI (1) SI3268374T1 (el)
TW (1) TWI701249B (el)
UA (1) UA121493C2 (el)
WO (1) WO2016146583A1 (el)
ZA (1) ZA201705561B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
WO2019057821A1 (en) 2017-09-20 2019-03-28 Lead Discovery Center Gmbh COUMARIN DERIVATIVES, PROCESSES FOR PREPARING THEM AND USES THEREOF IN THE TREATMENT OF CANCER
US10703735B2 (en) 2018-07-25 2020-07-07 Lead Discovery Center Gmbh 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer
US20220119376A1 (en) * 2018-09-07 2022-04-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compounds acting on crbn proteins
WO2020188049A1 (en) 2019-03-20 2020-09-24 Lead Discovery Center Gmbh Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer
MX2022011615A (es) 2020-05-20 2022-12-15 AMO Ireland Derivados de azacoumarina y azatiocumarina para uso en dispositivos ópticamente activos.
CN115960112B (zh) * 2023-02-03 2024-02-20 北京大学深圳医院（北京大学深圳临床医学院） 一种花椒毒醇衍生物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5729765A (en) 1980-10-08 1982-02-17 Yuuichi Yanagi Melting of snow on roof
US6861405B2 (en) 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
AUPS127202A0 (en) 2002-03-20 2002-04-18 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic ion channel blocking agents and methods of use thereof
US7772408B1 (en) 2002-08-29 2010-08-10 The Regents Of The University Of California Substituted 5-alkoxypsoralens as inhibitors of potassium channel activity in lymphocytes and other cells
JP2006515274A (ja) 2002-10-08 2006-05-25 マサチューセッツ・インスティテュート・オブ・テクノロジー コレステロール輸送の調節のための化合物
ITPD20020325A1 (it) 2002-12-18 2004-06-19 Consorzio Interuniversitario Nazionale La Chimic Sintesi di aniline funzionalizzate mono-n-sostituite.
CN100486245C (zh) 2003-07-31 2009-05-06 中兴通讯股份有限公司 一种支持多媒体消息版权保护的多媒体消息业务实现方法
US7557138B2 (en) 2004-10-04 2009-07-07 The Regents Of The University Of California 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel
WO2006096911A1 (en) 2005-03-15 2006-09-21 Harvey Andrew J Novel potassium channel blockers and uses thereof
CN101232886A (zh) 2005-08-17 2008-07-30 索尔瓦药物有限公司 使用钾通道抑制性化合物的方法
WO2007139771A1 (en) 2006-05-22 2007-12-06 The Johns Hopkins University Kv channels in neurodegeneration and neuroprotection
US8309545B2 (en) 2006-10-04 2012-11-13 Bionomics Limited Benzofuran potassium channel blockers and uses thereof
US8217189B2 (en) 2006-10-04 2012-07-10 Bionomics Limited Chromenone potassium channel blockers and uses thereof
CN101307056B (zh) * 2007-05-16 2011-04-27 中国科学院上海药物研究所 线型呋喃香豆素衍生物、其制备方法和用途、以及包含该衍生物的药物组合物
CA2701579A1 (en) 2007-10-04 2009-04-09 Bionomics Ltd. Novel aryl potassium channel blockers and uses thereof
US9114102B2 (en) 2007-11-07 2015-08-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of inhibiting ABCG2 and related treatments
EP2303850A4 (en) 2008-06-13 2012-10-31 Bionomics Ltd NOVEL BLOCKERS OF THE POTASSIUM CHANNEL AND THEIR USES
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
ES2345527B1 (es) 2008-10-08 2011-09-08 Hospital Clinic I Provincial De Barcelona Sustancias bloqueadoras de los canales kv 1.3 para el tratamiento de enfermedades asociadas a hiperplasia de la intima.
AR074558A1 (es) 2008-12-12 2011-01-26 Solvay Pharm Bv Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
US8859207B2 (en) 2009-09-15 2014-10-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
CN102091067B (zh) * 2009-12-09 2013-04-10 中国科学院上海药物研究所 呋喃香豆素类化合物在制备药物中的新用途
WO2011073273A1 (en) 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators
WO2011073269A1 (en) 2009-12-16 2011-06-23 Evotec Ag Piperidine aryl sulfonamide derivatives as kv1.3 modulators
WO2011073277A1 (en) 2009-12-16 2011-06-23 Evotec Ag PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS Kv1.3 MODULATORS
US9737585B2 (en) 2011-03-02 2017-08-22 Bioincept, Llc Compositions and methods for treatment of intracellular damage and bacterial infection
US20140171455A1 (en) * 2011-06-09 2014-06-19 The Regents Of The University Of California Reduction of Microglia-Mediated Neurotoxicity by Kv1.3 Inhibition
RU2014117558A (ru) 2011-10-03 2015-11-10 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Лечение ожирения и нарушений, связанных с ожирением, путем нацеливания фармакологических агентов на калиевые каналы
BR112018069854A2 (pt) * 2016-03-31 2019-01-29 Toray Industries métodos para produzir proteína, xilo-oligossacarídeos e glicose, método para suprimir a diminuição na saturação de oxigênio dissolvido ao cultivar um fungo e composição de celulase

Also Published As

Publication number Publication date
RS59758B1 (sr) 2020-02-28
US20200339592A1 (en) 2020-10-29
EA201791816A1 (ru) 2018-04-30
IL254391A0 (en) 2017-11-30
CN107548397A (zh) 2018-01-05
PH12017501652A1 (en) 2018-03-12
UA121493C2 (uk) 2020-06-10
AU2016232338A1 (en) 2017-10-05
PH12017501652B1 (en) 2018-03-12
SG11201707284PA (en) 2017-10-30
JP6506409B2 (ja) 2019-04-24
US10822345B2 (en) 2020-11-03
ES2762938T3 (es) 2020-05-26
LT3268374T (lt) 2020-03-10
TWI701249B (zh) 2020-08-11
WO2016146583A1 (en) 2016-09-22
SI3268374T1 (sl) 2020-03-31
EP3268374B1 (en) 2019-09-25
IL254391B (en) 2021-02-28
CN107548397B (zh) 2020-12-29
US20180051034A1 (en) 2018-02-22
ZA201705561B (en) 2020-01-29
US20190185483A1 (en) 2019-06-20
JP2018507892A (ja) 2018-03-22
BR112017019439A2 (pt) 2018-05-15
EP3268374A1 (en) 2018-01-17
HRP20192258T1 (hr) 2020-03-20
EA037194B1 (ru) 2021-02-18
PT3268374T (pt) 2019-12-23
MX2017011650A (es) 2018-02-09
TW201639843A (zh) 2016-11-16
US10723743B2 (en) 2020-07-28
US20200377514A1 (en) 2020-12-03
HK1243997B (zh) 2020-06-26
KR20170137056A (ko) 2017-12-12
CA2979503A1 (en) 2016-09-22
DK3268374T3 (da) 2020-01-02
PL3268374T3 (pl) 2020-05-18
AU2016232338B2 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
CY1122470T1 (el) Αναστολεις kv1.3 και η ιατρικη εφαρμογη αυτων
CY1126106T1 (el) Υποκατεστημενοι 2-αζαδικυκλοι και χρηση αυτων ως ρυθμιστες υποδοχεα ορεξινης
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
PE20160995A1 (es) Inhibidores de syk
CY1122201T1 (el) Παραγωγα βενζοδιοξολιου ως αναστολεις φωσφοδιεστερασης
CY1123154T1 (el) Παραγοντας ενισχυσης της επιδρασης αποκαταστασης μετα απο νευρικη βλαβη που περιλαμβανει ενα παραγωγο αλκυλαιθερα ή ενα αλας αυτου
PH12017500658B1 (en) Spirodiamine derivatives as aldosterone synthase inhibitors
PE20181024A1 (es) Derivados de ciclohexano sustituido con amido
CU20170164A7 (es) Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen
AR083169A1 (es) Compuestos para tratar enfermedades neurodegenerativas
EA201691302A1 (ru) Новые гетероциклические соединения
EA201591586A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
ES2684517T3 (es) Compuestos de heterociclilo como inhibidores de MEK
CY1124058T1 (el) Διαδικασια κρυσταλλωσης των παραγωγων αριπιπραζολης σε φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας
AR093184A1 (es) Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden
CY1120420T1 (el) Παραγωγα σουλφονυλοπιπεριδινης και χρηση αυτων πα την αγωγη νοσων με τη μεσολαβηση προκινετισινης
CY1119583T1 (el) Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα
CY1113812T1 (el) Ετεροκυκλικη ενωση και φαρμακευτικη συνθεση αυτης
MX2016007567A (es) Un nuevo compuesto de triazolo-piridina.
PE20190979A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
SV2017005381A (es) Compuestos de imidazopiridazina
AR098871A1 (es) Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
CY1121147T1 (el) Νεες συντηγμενες ενωσεις ιμιδαζοβενζοθειαζολιου
CY1119296T1 (el) Ενωση δικαρβοξυλικου οξεος